Clinical Trials Logo

Angiogenesis clinical trials

View clinical trials related to Angiogenesis.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05595889 Not yet recruiting - Clinical trials for Small Cell Lung Cancer

Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer

Start date: December 1, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the clinical efficacy and safety of surufatinib combined with irinotecan in the second line treatment of small cell lung cancer.

NCT ID: NCT05493046 Not yet recruiting - Muscle Weakness Clinical Trials

Interactive Hand Exercise Game on Grip Strength and Vascular Maturation

Start date: August 2022
Phase: N/A
Study type: Interventional

Hemodialysis is currently the most commonly used renal replacement therapy. Compared with arteriovenous graft, central venous catheter, and autologous arteriovenous fistula, the possibility of postoperative re-dredging is low and there are few complications, so isometric hand exercise training is the first choice for hemodialysis strategy. The intervention of smart technology has greatly improved the treatment effect and quality of life of patients, and it has unique advantages when applied to health care or behavior change intervention programs. This study expects to enhance hand grip strength through interactive hand exercise games combined with grip strength equipment, thereby increasing the vascular maturity of patients with postoperative autologous arteriovenous fistula, and enhancing the motivation of patients to participate.

NCT ID: NCT04807166 Not yet recruiting - Ovarian Neoplasms Clinical Trials

Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer

Start date: June 1, 2021
Phase: Phase 2
Study type: Interventional

It has been reported that antiangiogenic drugs combined with chemotherapy as first-line treatment, and subsequent antiangiogenic drugs as maintenance therapy for ovarian cancer can achieve better clinical benefits. Therefore, this study is expected to investigate the efficacy and safety of anlotinib combined with carboplatin/paclitaxel as first-line treatment in patients with advanced ovarian cancer.

NCT ID: NCT02865304 Not yet recruiting - Breast Cancer Clinical Trials

The Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative MBC Patients

Start date: December 2016
Phase: Phase 3
Study type: Interventional

The purpose of the present study was to prospectively evaluate the efficacy and safety of endostar, a recombinant product of endostatin, combined with taxane-based regimens for HER-2 negative metastatic breast cancer (MBC) patients.